An up­date on the End­points busi­ness mod­el — and how your com­pa­ny can di­rect­ly sup­port it

Pic­tured: The print-op­ti­mized ver­sion of End­points’ 2018 New Drug Ap­provals re­port. All paid sub­scribers will re­ceive a di­rect link to down­load the PDF + a copy of all our Q1 pay­wall sto­ries in print­able form, too.

Sign-up for En­ter­prise (com­pa­ny plan)
Sign-up for In­sid­er (in­di­vid­ual plan)


I want to give read­ers an up­date on the busi­ness front at End­points News, which is strong.

Two and a half years in — we’re prof­itable, about 14 peo­ple on the team and grow­ing, and 75,000 unique bio­phar­ma read­ers con­sume our news across all plat­forms on a week­ly ba­sis. Of that, 31,000 are what we con­sid­er “ba­sic sub­scribers” who re­ceive our dai­ly email re­ports and have opened or clicked on them in the last month, but haven’t up­grad­ed to paid sta­tus. And at the top we have 8,300 pre­mi­um sub­scribers who ei­ther di­rect­ly sup­port the work or are em­ployed at a com­pa­ny that does.

We reg­u­lar­ly scrub our email read­er­ship, too.

We’ve built a glob­al events fran­chise and con­vened over 2,000 at­ten­dees over the last 12 months in San Fran­cis­co, Boston, Lon­don, and Shang­hai. Lat­er this month we’ll be an­nounc­ing venues and dates for our en­tire 2019 line­up.

John Car­roll speaks at the US-Chi­na Bio­phar­ma In­no­va­tion and In­vest­ment Sum­mit in Shang­hai on Oc­to­ber 23, 2018

Click on the im­age to see the full-sized ver­sion


And we’ve done all of this with­out rais­ing any VC cash.

End­points is built to with­stand the storms en­velop­ing dig­i­tal me­dia to­day thanks to the di­rect sup­port of our En­ter­prise and In­sid­er sub­scribers.  We’re hir­ing new jour­nal­ists, plan to dou­ble the au­di­ence, and have moved in­to a new head­quar­ters in Lawrence, Kansas that’ll serve as the nerve-cen­ter for End­points’ next stage of in­no­va­tion. New hires in mar­ket­ing, sales, and op­er­a­tions are in the works now to sup­port that. There’s a web­site re­vamp on tap. And there’s just so much more news we’d like to cov­er in trans­la­tion­al sci­ence and out­sourc­ing.

Most im­por­tant­ly: Our fi­nan­cial in­cen­tives are tied to pro­duc­ing a jour­nal­ism prod­uct that serves the core bio­phar­ma read­er.

Haven’t joined yet? Now is a great time and you can see one of the ben­e­fits above: a print (yes, print!) ver­sion of the 2018 class of new drug ap­provals. You’ll al­so get ac­cess to the lat­est edi­tion of bio­phar­ma’s top 100 VCs, and the en­tire pay­wall li­brary.

The most im­por­tant way you can di­rect­ly sup­port End­points is hav­ing your com­pa­ny sub­scribe to our $1,000/year flat-rate En­ter­prise plan (signup link). That’s an “un­lim­it­ed li­cense” for every em­ploy­ee un­der your cor­po­rate ban­ner. All of your col­leagues get ac­cess to pay­wall con­tent, reprint rights, PDF ex­port, and your HR team gets two pre­mi­um job post­ings at End­points Ca­reers. We have a VIP sup­port team who’ll work with you to get End­points set up for the rest of your team, too.

It’s a great val­ue, and you’re sup­port­ing the most im­por­tant part of our mod­el. The pric­ing is trans­par­ent and so is our re­new­al process.

For in­di­vid­u­als, we of­fer the In­sid­er plan at $200/year. Ex­tra ben­e­fits on top of the pay­wall ac­cess in­clude dis­count­ed rates to our ma­jor glob­al events line­up.

We’re al­so start­ing a se­ries of sub­scriber-on­ly net­work­ing mix­ers for In­sid­ers. The very first one will be in Durham, NC on Thurs­day Feb­ru­ary 21 at 6pm. I’ll be there along with our VP/Part­ner­ships Mike Peck. In­sid­ers will get an email next week with signup de­tails on this one and our fu­ture slate.

Grow­ing Plans

We’re go­ing through a ma­jor plat­form over­haul this year.

The look and feel of End­points hasn’t changed since we launched in June 2016. The orig­i­nal goal of our de­sign is to de­liv­er news with­out un­nec­es­sary or­na­ments, with a user ex­pe­ri­ence that feels fa­mil­iar no mat­ter what de­vice you’re on. But we’ve pub­lished over 5,000 news ar­ti­cles and near­ly 700 dai­ly re­ports now in the End­points style, and with that ex­pe­ri­ence we’ve iden­ti­fied a num­ber of ar­eas we can im­prove on. Some of it will be in­cre­men­tal like bet­ter search and im­prov­ing the archives. Oth­ers will be more vis­i­ble and feel like brand new fea­tures.

Ad­ver­tis­ing

Sub­scrip­tions are the lifeblood of this com­pa­ny. But in or­der to de­vel­op a sus­tained im­pact be­fit­ting a ma­jor news or­ga­ni­za­tion, ar­ti­cles must be able to trav­el far and wide, eas­i­ly dis­cov­er­able by new au­di­ences. Oth­er­wise, we run the risk of be­com­ing an in­sid­ers-on­ly re­port.

That is where ad­ver­tis­ing comes in. But noth­ing we do there is tra­di­tion­al.

I don’t be­lieve in squeez­ing web pages hard for lit­tle juice. That’s es­sen­tial­ly what many news pub­lish­ers do when you see pro­mot­ed links and ads that are at best ir­rel­e­vant and at worst have fol­lowed you around the In­ter­net to sell you some­thing you searched on ear­li­er. That kind of ap­proach cheap­ens the qual­i­ty of the con­tent sur­round­ing it, in my view. It has no place on a busi­ness news web­site.

Every ad unit you see on End­points is pur­chased in-house. These are high qual­i­ty im­pres­sions that are rel­e­vant to bio­phar­ma, brought to you by ad­ver­tis­ers that have been vet­ted. Our busi­ness team is led by Mike Peck, who comes to End­points af­ter serv­ing as a VP at Forbes and the New York Times. Mar­ket­ing pros can reach him at mike@end­pointsnews.com.

Busi­ness Mod­el

Sub­scrip­tions, events, ad­ver­tis­ing — in or­der of im­por­tance, that is the End­points busi­ness mod­el. Our mis­sion is to pro­duce the best dai­ly news re­port in bio­phar­ma, writ­ten for our core read­ers, but to make it as wide­ly avail­able as pos­si­ble so it has an im­pact and is dis­cov­er­able by new read­ers.

If you need End­points, we def­i­nite­ly need you. Again the best way to sup­port us is hav­ing your com­pa­ny sub­scribe to our $1,000/year flat-rate En­ter­prise plan (signup link). In­di­vid­u­als can signup for In­sid­er here.

To all of you who’ve joined — thank you. We’re build­ing some­thing to­geth­er.

Health­care Dis­par­i­ties and Sick­le Cell Dis­ease

In the complicated U.S. healthcare system, navigating a serious illness such as cancer or heart disease can be remarkably challenging for patients and caregivers. When that illness is classified as a rare disease, those challenges can become even more acute. And when that rare disease occurs in a population that experiences health disparities, such as people with sickle cell disease (SCD) who are primarily Black and Latino, challenges can become almost insurmountable.

Jacob Van Naarden (Eli Lilly)

Ex­clu­sives: Eli Lil­ly out to crash the megablock­buster PD-(L)1 par­ty with 'dis­rup­tive' pric­ing; re­veals can­cer biotech buy­out

It’s taken 7 years, but Eli Lilly is promising to finally start hammering the small and affluent PD-(L)1 club with a “disruptive” pricing strategy for their checkpoint therapy allied with China’s Innovent.

Lilly in-licensed global rights to sintilimab a year ago, building on the China alliance they have with Innovent. That cost the pharma giant $200 million in cash upfront, which they plan to capitalize on now with a long-awaited plan to bust up the high-price market in lung cancer and other cancers that have created a market worth tens of billions of dollars.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

David Meek, new Mirati CEO (Marlene Awaad/Bloomberg via Getty Images)

Fresh off Fer­Gene's melt­down, David Meek takes over at Mi­rati with lead KRAS drug rac­ing to an ap­proval

In the insular world of biotech, a spectacular failure can sometimes stay on any executive’s record for a long time. But for David Meek, the man at the helm of FerGene’s recent implosion, two questionable exits made way for what could be an excellent rebound.

Meek, most recently FerGene’s CEO and a past head at Ipsen, has become CEO at Mirati Therapeutics, taking the reins from founding CEO Charles Baum, who will step over into the role of president and head of R&D, according to a release.

FDA hands ac­cel­er­at­ed nod to Seagen, Gen­mab's so­lo ADC in cer­vi­cal can­cer, but com­bo stud­ies look even more promis­ing

Biopharma’s resident antibody-drug conjugate expert Seagen has scored a clutch of oncology approvals in recent years, finding gold in what are known as “third-gen” ADCs. Now, another of their partnered conjugates is ready for prime time.

The FDA on Monday handed an accelerated approval to Seagen and Genmab’s Tivdak (tisotumab vedotin-tftv, or “TV”) in second-line patients with recurrent or metastatic cervical cancer who previously progressed after chemotherapy rather than PD-(L)1 systemic therapy, the companies said in a release.

Dave Lennon, former president of Novartis Gene Therapies

Zol­gens­ma patent spat brews be­tween No­var­tis and Re­genxbio as top No­var­tis gene ther­a­py ex­ec de­parts

Regenxbio, a small licensor of gene therapy viral vectors spun out from the University of Pennsylvania, is now finding itself in the middle of some major league patent fights.

In addition to a patent suit with Sarepta Therapeutics from last September, Novartis, is now trying to push its smaller partner out of the way. The Swiss biopharma licensed Regenxbio’s AAV9 vector for its $2.1 million spinal muscular atrophy therapy Zolgensma.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.

Volker Wagner (L) and Jeff Legos

As Bay­er, No­var­tis stack up their ra­dio­phar­ma­ceu­ti­cal da­ta at #ES­MO21, a key de­bate takes shape

Ten years ago, a small Norwegian biotech by the name of Algeta showed up at ESMO — then the European Multidisciplinary Cancer Conference 2011 — and declared that its Bayer-partnered targeted radionuclide therapy, radium-223 chloride, boosted the overall survival of castration-resistant prostate cancer patients with symptomatic bone metastases.

In a Phase III study dubbed ALSYMPCA, patients who were treated with radium-223 chloride lived a median of 14 months compared to 11.2 months. The FDA would stamp an approval on it based on those data two years later, after Bayer snapped up Algeta and christened the drug Xofigo.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.

Rafaèle Tordjman (Jeito Capital)

Con­ti­nu­ity and di­ver­si­ty: Rafaèle Tord­j­man's women-led VC firm tops out first fund at $630M

For a first-time fund, Jeito Capital talks a lot about continuity.

Rafaèle Tordjman had spotlighted that concept ever since she started building the firm in 2018, promising to go the extra mile(s) with biotech entrepreneurs while pushing them to reach patients faster.

Coincidentally, the lack of continuity was one of the sore spots listed in a report about the European healthcare sector published that same year by the European Investment Bank — whose fund is one of the LPs, alongside the American pension fund Teacher Retirement System of Texas and Singapore’s Temasek, to help Jeito close its first fund at $630 million (€534 million). As previously reported, Sanofi had chimed in €50 million, marking its first investment in a French life sciences fund.

Mi­rati tri­umphs again in KRAS-mu­tat­ed lung can­cer with a close­ly watched FDA fil­ing now in the cards

After a busy weekend at #ESMO21, which included a big readout for its KRAS drug adagrasib in colon cancer, Mirati Therapeutics is ready to keep the pressure on competitor Amgen with lung cancer data that will undergird an upcoming filing.

In topline results from a Phase II cohort of its KRYSTAL-1 study, adagrasib posted a response rate of 43% in second-line-or-later patients with metastatic non-small cell lung cancer containing a KRAS-G12C mutation, Mirati said Monday.

As­traZeneca, Dai­ichi Sanky­o's ADC En­her­tu blows away Roche's Kad­cy­la in sec­ond-line ad­vanced breast can­cer

AstraZeneca and Japanese drugmaker Daiichi Sankyo think they’ve struck gold with their next-gen ADC drug Enhertu, which has shown some striking data in late-stage breast cancer trials and early solid tumor tests. Getting into earlier patients is now the goal, starting with Enhertu’s complete walkover of a Roche drug in second-line breast cancer revealed Saturday.

Enhertu cut the risk of disease progression or death by a whopping 72% (p=<0.0001) compared with Roche’s ADC Kadcyla in second-line unresectable and/or metastatic HER2-positive breast cancer patients who had previously undergone treatment with a Herceptin-chemo combo, according to interim data from the Phase III DESTINY-Breast03 head-to-head study presented at this weekend’s #ESMO21.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.